REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Peptide Library

Humanin

HN / HNG / Humanin G

Longevity & Anti-Aging

Humanin is a 24-amino acid mitochondrial-derived peptide (MDP) encoded within the 16S ribosomal RNA gene of mitochondrial DNA, first discovered in 2001 from surviving neurons in Alzheimer's disease brains. It exhibits potent neuroprotective, anti-apoptotic, and cytoprotective properties across multiple organ systems through interactions with IGFBP-3, BAX, and the formyl peptide receptor-like 1 (FPRL1). Research interest has expanded from neurodegeneration to encompass metabolic disease, cardiovascular protection, and aging biology.

Mechanism of Action

Mitochondria-derived micropeptide encoded in the 16S rRNA region. Neuroprotective through binding to IGFBP-3 (blocking apoptosis), activating STAT3 signaling, and modulating BAX-mediated cell death. Also improves insulin sensitivity and reduces amyloid-beta toxicity.

Research Protocols

For research purposes only. Not medical advice.

Research protocols are primarily preclinical. Humanin analogs (HNG, HNGF6A) used at 1-4mg/kg in animal models. Human dosing not established. Intranasal and subcutaneous routes studied.

Research Notes

Clinical Research Status

Humanin remains in the preclinical and early translational research phase, with no completed human clinical trials as of current literature. Observational studies have found that circulating humanin levels decline with age and correlate inversely with markers of cognitive decline and metabolic dysfunction. Several humanin analogs with enhanced potency and stability, particularly HNG (S14G-Humanin), have been developed to overcome the native peptide's short half-life and advance toward clinical testing.

Key Published Findings

The original discovery by Bhimori Hashimoto (2001) demonstrated that humanin specifically protected neurons against amyloid-beta toxicity, presenilin mutant-induced apoptosis, and other Alzheimer's-related insults. Subsequent research revealed humanin acts as an insulin sensitizer, reducing hepatic glucose production and improving glucose tolerance in animal models of diabetes. Studies in cardiovascular models show humanin protects against ischemia-reperfusion injury, reduces atherosclerotic plaque formation, and inhibits vascular smooth muscle cell apoptosis.

Safety Profile

As an endogenously produced peptide, humanin is considered to have a favorable safety profile, though systematic toxicology studies in humans have not been conducted. The primary theoretical concern involves its anti-apoptotic properties potentially interfering with tumor suppression mechanisms, though some evidence suggests it may actually enhance certain anti-cancer immune responses. No significant adverse effects have been reported in animal studies at supraphysiological doses, though long-term exposure data remains limited.

Comparison to Related Compounds

Humanin is the founding member of the mitochondrial-derived peptide family, which also includes MOTS-c (a 16-amino acid exercise mimetic peptide) and the SHLPs (Small Humanin-Like Peptides 1-6). Unlike exogenous neuroprotective peptides such as Cerebrolysin or Semax, humanin represents an endogenous protective signal that declines with mitochondrial aging. The analog HNG is approximately 1000-fold more potent than native humanin, making it more practical for research applications.

Community Observations

Interest in humanin within longevity research communities centers on its role as a biomarker and potential therapeutic for mitochondrial aging. Due to extremely limited commercial availability and the early stage of research, human experimentation outside academic settings is rare. The peptide's connection to centenarian genetics (elevated humanin levels correlate with exceptional longevity) has generated significant interest in the anti-aging research community.

Half-Life

~30-60 minutes

Reconstitution

Sterile saline or bacteriostatic water

Storage

Lyophilized

Store at -20C. Sensitive to freeze-thaw cycles.

Reconstituted

Refrigerate 2-8C. Use within 7 days.

US Legal Status

Research chemical (not FDA-approved)

Also Known As

HNHNGHumanin G

PeptideVault provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer